Clinical trials: Tislelizumab
Gastroesophageal Adenocarcinoma
Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma
ARMANI-2/ENGIC8 is a randomized, open-label, phase III trial evaluating a switch maintenance strategy in patients with previously untreated, locally advanced unresectable or metastatic, HER2-negative and PD-L1-positive…
- Trial name
- ARMANI-2 (NCT07763171)
- Testing
- FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), CAPOX (oxaliplatin/capecitabine), CDDP, 5 Fu
- Where
- 42 sites in Germany, Italy and 1 more
- Volunteers
- 244 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Cancer
A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects
This study will describe the efficacy of pamiparib in combination with tislelizumab in patients with advanced tumours harbouring molecular profiles consistent with homologous recombination deficiency (HRD), agnostic of tumour…
- Trial name
- IMPARP-HRD (NCT04985721)
- Testing
- Pamiparib, Tislelizumab
- Where
- 3 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Lung Cancer, Non-small Cell Lung Cancer
Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer
This phase II study aims to evaluate the efficacy and safety of low-dose radiation + SBRT + Tislelizumab plus platinum-based chemotherapy as neoadjuvant therapy for stage II-III non-small cell lung cancer.
- Trial name
- NCT06877299
- Testing
- Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan University
Gastric Cancer
Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore
This is a multicenter, prospective, phase II clinical study to evaluate the efficacy and safety of intensive treatment with lenvatinib plus tislelizumab and CapeOX as first-line treatment for advanced gastric cancer or…
- Trial name
- NCT06157996
- Testing
- lenvatinib and tislelizumab plus CapeOX chemotherapy, tislelizumab plus CapeOX chemotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Nanfang Hospital, Southern Medical University
NK/T Cell Lymphoma Nos
Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma
This is a single-arm, open-label, multicenter, phase 2 study designed to evaluate the efficacy and safety of brentuximab vedotin combined with PD-1 inhibitor tislelizumab in Chinese patients with relapsed/refractory CD30+ NK/CL.
- Trial name
- NCT05316246
- Testing
- Brentuximab Vedotin in Combination with Tislelizumab
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer
This study is a prospective, single arm, phase II clinical trial. We plan to include 36 newly diagnosed ES-SCLC patients who meet the inclusion criteria and receive induction therapy (tislelizumab+EP regimen, 4-6 cycles).
- Trial name
- NCT07425795
- Testing
- Tislelizumab Combined With Chemotherapy
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Chongqing University Cancer Hospital
Non-Small Cell Lung Cancer (NSCLC)
MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC
Neoadjuvant immunotherapy combined with platinum-based doublet chemotherapy has been established as the standard of care for driver-gene-negative (EGFR/ALK wild-type) stage II-IIIB non-small cell lung cancer (NSCLC), yielding…
- Trial name
- NCT07885709
- Testing
- PD-1 inhibitor, Carboplatin, Nab-paclitaxel
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Advanced Malignant Solid Tumors
A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors
The goal of this clinical trial is to learn the safety, tolerability, pharmacokinetic characteristics and efficacy of FC084CSA in combination with Tislelizumab in patients with advanced malignant solid tumors.
- Trial name
- NCT06499350
- Testing
- FC084CSA+Tislelizumab combination (dose escalation), RP2D of FC084CSA+Tislelizumab combination (dose expansion)
- Where
- China
- Volunteers
- 33 people
- Sponsor
- FindCure Biosciences (ZhongShan) Co., Ltd.
Colon Adenocarcinoma
HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer
The purpose of this clinical trial is to learn the safety and efficacy of HDAC inhibitors in combination with neoadjuvant immunochemotherapy compared to neoadjuvant therapy in the treatment of locally advanced colon cancer.
- Trial name
- NCT06709885
- Testing
- Chidamide + Tislelizumab + chemotherapy (CapeOX ), CapeOX
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Rectal Neoplasms
Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer
This study aims to evaluate the efficacy and safety of tislelizumab combined with simultaneous integrated boost intensity-modulated radiotherapy in treating locally advanced rectal cancer.
- Trial name
- NCT06017583
- Testing
- Tislelizumab, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Yong Zhang,MD
Colorectal Cancer
Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases
This study attempts to employ a combination therapy using rhG-CSF, IL-2, and PD-1 inhibitors, aiming to overcome the limitations of monotherapy in immunotherapy through multi-faceted immune regulation.
- Trial name
- NCT06504901
- Testing
- Tislelizumab, Interleukin-2, Capecitabine
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma
Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)
Definitive chemoradiotherapy (CRT) is the standard treatment option for unresectable locally advanced esophageal cancer (EC). However, as high as more than 40% of EC patients experienced locoregional recurrence after concurrent…
- Trial name
- EC-CRT-002 (NCT05520619)
- Testing
- Paclitaxel, Cisplatin, tislelizumab, Radiotherapy
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Sun Yat-sen University
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced…
- Conditions
- KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
- Trial name
- KontRASt-01 (NCT04699188)
- Testing
- JDQ443, TNO155, tislelizumab
- Where
- 38 sites in United States, Australia and 14 more
- Volunteers
- 344 people
- Sponsor
- Novartis Pharmaceuticals
Mid-low Rectal Cancer
Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer
To explore the complete response (CR) rate of modified short-course radiotherapy combined with CAPOX and tislelizumab for locally Advanced Mid-low Rectal Cancer
- Trial name
- NCT06333769
- Testing
- Short-course Radiotherapy, Tislelizumab, Capecitabine
- Where
- 3 sites in China
- Volunteers
- 38 people
- Sponsor
- Fujian Cancer Hospital
Hepatocellular Carcinoma (HCC)
Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
To evaluate the efficacy and safety of lenvatinib plus tislelizumab versus lenvatinib alone for patients with advanced hepatocellular carcinoma (HCC) who have progressed on prior systemic treatment with Anti-PD1/PD-L1 plus…
- Trial name
- LEAF-01 (NCT07047586)
- Testing
- Tislelizumab, Lenvatinib
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Fudan University
Colorectal Cancer, Liver Metastasis
LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis
In recent years, growing evidences have demonstrated promising synergistic antitumor effects of radiotherapy combined with immunotherapy.
- Conditions
- Colorectal Cancer, Liver Metastasis, LDRT
- Trial name
- NCT06848465
- Testing
- Low Dose Radiotherapy, Short course Radiotherapy, XELOX
- Where
- 2 sites in China
- Volunteers
- 9 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Immune-related Adverse Event, Malignant Solid Tumors
The Effect of Serum Ferritin in irAE
This is a prospective clinical study to clarify serum ferritin as a biomarker for the diagnosis, differential diagnosis and prognosis of immune-related adverse event(irAE).
- Conditions
- Immune-related Adverse Event, Malignant Solid Tumors, Acute Leukemia, Serum Ferritin
- Trial name
- NCT06702566
- Testing
- PD-1 and PD-L1 inhibitor, Targeted drugs, chemotherapy drugs
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Unresectable Metastatic Colorectal Cancer, Microsatellite Stable (MSS) Colorectal Cancer (CRC)
SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.
SBRT Combined with CAPEOX, Bevacizumab, and PD-1 Inhibitor in RAS-Mutant, Microsatellite Stable (MSS), Unresectable Metastatic Colorectal Cancer (mCRC): a Single-center, Single-arm, Open-label Clinical Trail
- Conditions
- Unresectable Metastatic Colorectal Cancer, Microsatellite Stable (MSS) Colorectal Cancer (CRC), RAS-mutant Colorectal Cancer
- Trial name
- NCT06835179
- Testing
- SBRT, PD-1 Inhibitors, CapeOX + bevacizumab
- Volunteers
- 28 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Locally Advanced Rectal Cancer
Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer
This study is a single-center, prospective, open-label, randomized controlled clinical study, and the purpose of this study was to compare the pathological complete response rate (PCR) of patients with locally advanced rectal…
- Trial name
- NCT05086627
- Testing
- Tislelizumab, Short-course radiotherapy, Capecitabine+Oxaliplatin
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Hebei Medical University Fourth Hospital
Gallbladder Cancer, Cholangiocarcinoma
Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)
The goal of this clinical trial is to evaluate the efficacy and safety of combining Gemcitabine, nab-Paclitaxel, Lenvatinib, and Tislelizumab in adults aged 18-75 years with advanced unresectable biliary tract malignancies…
- Trial name
- GALENT-BT (NCT06963060)
- Testing
- Gemcitabine nab-PaclitaxelLenvatinibTislelizumab
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Wei Gong